Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2012. Refer to TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (which replaced NICE TA241) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | dasatinib (Sprycel®) | |
| Formulation | film-coated tablet | |
| Reference number | 103 | |
| Indication | Treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib mesilate |
|
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Full | |
| Status | Superseded | |
| Advice number | 1307 | |
| NMG meeting date | 13/11/2007 | |
| AWMSG meeting date | 11/12/2007 | |
| Ratification by Welsh Government | 16/01/2008 | |
| Date of issue | 18/01/2008 | |
| NICE guidance | ||